Biomarkers and Targeted Therapies in Metastatic Colon Cancer

This chapter discusses the importance of biomarker testing in metastatic colon cancer, including RAS and BRAF mutations, HER2 status, PDL1, MSI status, and NTRAC fusions. It also explores the use of VEGF inhibitors and EGFR inhibitors as targeted therapies.